Daily Biotech Movers — 2026-07-07: A $10B Vertex–Crinetics Buyout, a TVRD Phase 1 Win, and a CollPlant Dilution Vote

Tuesday, July 7, 2026 was a catalyst-driven day for biotech equities — a sharp break from the 2026-07-06 zero-clean-catalyst tape. Of the 587 public companies we track, 302 finished up and 270 finished down, with a mean move of +0.62% and a median of +0.34%. The dispersion was wide — 142 names moved |%|>= 5% — and the composition was clean. The top three winners and top three losers were each anchored by a fresh, news-driven catalyst: a $10B all-cash acquisition (CRNX), a Phase 1 readout (TVRD), a credibility hire (AKTX), a 16.7x share-capital expansion vote (CLGN), a securities-fraud class-action probe (ELTX), and a profit-taking continuation (CV). The S&P 500 closed -0.48%; the XBI finished +1.90%; the IBB +1.50%; the XLV +1.53%. Healthcare outperformed the broad market despite the S&P dip — capital rotated into biotech on the Vertex–Crinetics news, with the small-cap XBI leading the broad-cap XLV and the IBB. Sector leaders: Antibodies +2.69% (n=42), RNA, Peptide & Gene Therapy +2.33% (n=27), Small Molecule Pharma +2.15% (n=154). Laggards: AI / Machine Learning -5.67% (n=6), Devices — Imaging -4.01% (n=8), Cannabis-related -4.04% (n=4).

Below is what moved, who drove it, and what the rotation into small-cap biotech on buyout news means for the next session.

The Distribution

Across 587 public biotech/life-sciences companies on 2026-07-07:
  302 up   (avg +4.32%)
  270 down (avg -3.51%)
  Median: +0.34%   Mean: +0.62%   StDev: 7.02%
  142 names moved |%|>= 5% (anomaly threshold)

The up/down ratio was 1.12:1 — modestly positive. The mean move on the upside (+4.32%) was meaningfully larger than the mean move on the downside (-3.51%), giving a positive skew. The 142-anomaly count is in line with the rolling-30-day median and well above the 110 of 2026-07-06. The 7.02% StDev is the headline number: the day produced a wider single-name dispersion than any session in the past week, which is the signature of a catalyst-driven tape with marquee single-stock flow (CRNX, TVRD) dominating the broad-sector signal. The sector averages tell the rotation story: Antibodies and RNA, Peptide & Gene Therapy led with broad participation (n=42 and n=27), while AI/ML and Devices — Imaging lagged. The day was driven by event-flow, not sector-momentum.

The 6 Classes of Mover Signal

The 142 anomalies collapse into the same 6 categories of signal, but the composition is shifted. Today is the first session in over a week where the top three winners are anchored by a Class-3 (Buyout / strategic capital) and a Class-2 (Single-stock clinical) catalyst — not mechanical flows. The prior pattern (2026-07-06: zero clean catalysts; 2026-07-02: one Phase-2 miss + one buyback + one continuation) was dominated by Class-1 (mechanical) and Class-5 (prior-cycle) signals. Tuesday was different.

1. Halt-release or reverse-split-adjacent. No clean Class-1 entry in the top six. This is the first session in the past week without a halt-release or pre-split run-up in the top movers. The market’s structural low-priced microcap squeezes (CELU, PFSA, BTAI, IVF) that anchored 2026-07-06 are absent from the top six on 2026-07-07. The absence is itself a signal — the catalyst tape took over from the mechanical tape, and the low-priced compliance-strained microcap complex gave back some of its prior-cycle squeeze flow.

2. Single-stock clinical / regulatory event. One of the top six sits here. Tvardi Therapeutics (TVRD, +54.23% on 24.17x volume, 5d +62.3%) ran on positive Phase 1 results for TTI-109, its next-generation STAT3 inhibitor and a phosphate prodrug of TTI-101. The Phase 1 readout confirmed three things: (a) rapid prodrug conversion to TTI-101 within two hours, (b) dose-proportional pharmacokinetics with plasma levels above the STAT3 IC50, and (c) an exploratory pharmacodynamic analysis showing reductions of up to 60% in STAT3-driven immune cell populations across Th17, Tfh, and B cell subsets — the target-engagement signature. The 24.17x volume is the day’s largest institutional flow, and the multi-day run-up (5d +62.3%) confirms the move has been building since the prodrug design was first announced. This is a clean Phase 1 catalyst with multiple positive signals (PK, target engagement, tolerability) on a previously thinly-traded microcap. The next value-driving event is the planned Phase 2 initiation in hepatocellular carcinoma and other STAT3-driven indications.

3. Buyout / strategic capital. One of the top six sits here, and it’s the day’s marquee move. Crinetics Pharmaceuticals (CRNX, +98.74% on 18.41x volume, 5d +126.1%) ran on Vertex Pharmaceuticals’ all-cash acquisition announcement: $85 per share, ~$10B total value, expected to close in Q3 2026. The deal hands Vertex Crinetics’ endocrine portfolio, including PALSONIFY (palsonify) for acromegaly, projected to generate over $5B in peak annual revenue. CRNX hit a 52-week high of $83.64 in after-hours trading and is now trading close to the $85 takeout price. This is one of the largest biotech acquisitions of 2026, ranking alongside AbbVie’s $10.9B Apogee deal (June 22) and the Definium–AbbVie transaction. The 18.41x volume is the institutional-grade confirmation of the deal tape — the market is treating this as a near-zero-risk arb to deal close. Watch the spread to $85: if it compresses to a few percent, the deal is considered clean; if it widens on regulatory or financing risk, the arb spread opens and creates a short opportunity.

4. Sector rotation — Antibodies and RNA/Peptide/Gene Therapy lead; AI/ML and Devices — Imaging lag. The sector-level average moves tell the rotation story:

• Antibodies: +2.69% (n=42) — broad-based, the day’s sector leader
• RNA, Peptide & Gene Therapy: +2.33% (n=27) — broad-based, with FHTX +18.81% and PYXS +24.80% contributing
• Small Molecule Pharma: +2.15% (n=154) — broad-based, the largest category
• Bioinformatics: +1.43% (n=4) — small sample
• Drug Delivery/Formulation: +0.55% (n=30) — broad-based

And the laggards:

• AI / Machine Learning: -5.67% (n=6) — small sample, the day’s worst sector
• Cannabis-related: -4.04% (n=4) — small sample
• Devices — Imaging: -4.01% (n=8) — small sample
• Genetics & Genomics: -3.68% (n=7)
• Devices — Drug Delivery: -2.02% (n=3) — small sample

The XBI (+1.90%) outperformed the IBB (+1.50%) and the XLV (+1.53%) — capital rotated into small-cap biotech on the CRNX news and the broad sector flow. The laggard reads (AI/ML, Cannabis, Devices — Imaging) are dominated by small samples (n=4 to n=8) and individual name drags; the broad-based sector reads (Antibodies, RNA, Small Molecule) are the more reliable signals. The bottom line: today’s rotation is from low-quality microcap and imaging-device laggards into revenue-positive or near-revenue Antibodies and RNA/Peptide/Gene Therapy, with the marquee Vertex–Crinetics deal providing the macro tailwind.

5. Sell-the-news / prior-cycle profit-taking. One of the top six sits here, though the prior-cycle anchor is much weaker than 2026-07-06. CapsoVision (CV, -14.22% on 1.78x volume, 5d -24.8%) is the continuation play: the 5d momentum (-24.8%) confirms a multi-week slide off the early-summer highs, and the 1.78x volume is moderate — institutional-grade but not capitulation-grade. No fresh July 7 catalyst was identified; the most recent operational disclosure is the March 26, 2026 Q4 2025 / full-year 2025 earnings release. The 12-month price chart shows the stock was up 57.76% over the prior 12 months and is now down 5.84% over the past 30 days, suggesting profit-taking on a longer-term gain. Signal class: Sell-the-news / profit-taking on a multi-week slide. Watch: the next material event is the Q2 2026 earnings release in early August. A clean print on capsule-endoscopy system placements and AtHome Capsule revenue would be the next value-creating event.

6. Stealth accumulation / distribution. Three names with |pct| < 3% but volume_ratio >= 3x. Worth watching for follow-through into next week.

• bioAffinity Technologies (BIAF, +2.70% on 5.12x volume) — flat price, 5x volume; possible institutional loading.
• Xilio Therapeutics (XLO, -1.38% on 4.95x volume) — flat price, 5x volume; possible institutional distribution or pre-clinical-event positioning.
• Compass Pathways (CMPS, +1.17% on 3.52x volume, 5d -13.8%) — flat price, 3.5x volume; 5d momentum is negative, suggesting distribution rather than accumulation. The 3.52x volume on flat price is the institutional-exit pattern.

Top 3 Winners — What Drove Them

Crinetics Pharmaceuticals (CRNX) — +98.74% on 18.41x volume

Crinetics Pharmaceuticals ran +98.74% on 18.41x volume on Tuesday, hitting a 52-week high of $83.64, after Vertex Pharmaceuticals announced an all-cash acquisition of Crinetics at $85 per share, valuing the company at approximately $10 billion. The deal is expected to close in Q3 2026 and hands Vertex Crinetics’ endocrine portfolio, including PALSONIFY (palsonify) for acromegaly, projected to generate over $5B in peak annual revenue. This is one of the largest biotech acquisitions of 2026, ranking alongside AbbVie’s $10.9B Apogee deal (June 22) and the Definium–AbbVie transaction as the year’s marquee strategic-capital prints. Signal class: Buyout / strategic capital. The 18.41x volume is the institutional-grade confirmation of the deal tape — the market is treating this as a near-zero-risk arb to deal close. The 5d momentum of +126.1% (the 5d column) indicates the market was positioning into the announcement over the past week. Watch: deal close expected Q3 2026. The arb spread to $85 should compress to a few percent as the deal progresses through regulatory review; if regulatory risk emerges, the spread widens and creates a short opportunity. Vertex (VRTX) is now a company with two consecutive marquee rare-disease commercial assets (Casgevy and PALSONIFY) targeting the endocrine and hemoglobinopathy markets — a strategic read is that Vertex is moving from cystic fibrosis to a multi-asset rare-disease commercial-stage platform. Sources: Intellectia: Crinetics Surges After $10 Billion Vertex Acquisition, Timothy Sykes: CRNX Soars As Vertex Launches $10B All-Cash Takeover, StocksToTrade: CRNX Soars On Vertex’s $10B Buyout And Tight Trading Range.

Tvardi Therapeutics (TVRD) — +54.23% on 24.17x volume

Tvardi Therapeutics ran +54.23% on 24.17x volume on Tuesday, the day’s largest single-stock flow, after announcing positive Phase 1 results for TTI-109, its next-generation STAT3 inhibitor. TTI-109 is a phosphate prodrug of TTI-101 designed to improve delivery and tolerability while preserving the parent compound’s mechanism of action. The Phase 1 study confirmed three key findings: (1) rapid prodrug conversion to TTI-101 within two hours, validating the prodrug design; (2) dose-proportional pharmacokinetics with plasma levels above the STAT3 IC50, confirming target-level exposure; and (3) reductions of up to 60% in STAT3-driven immune cell populations across Th17, Tfh, and B cell subsets in an exploratory pharmacodynamic analysis, confirming target engagement. The tolerability profile improved over TTI-101. Signal class: Single-stock clinical event. This is a clean Phase 1 readout with multiple positive signals (PK, target engagement, tolerability) on a previously thinly-traded microcap. The 5d momentum of +62.3% confirms the move is part of a multi-day run-up, not a one-day event — the prodrug design has been building credibility since the company’s earlier disclosures. Watch: the next value-driving event is the planned Phase 2 initiation in hepatocellular carcinoma and other STAT3-driven indications. STAT3 is a notoriously hard-to-drug target (the target sits inside the cell, not on the surface), and a clean Phase 1 PK/PD/tolerability readout is a meaningful de-risking event for the prodrug design. Sources: InvestorIdeas: Tvardi Soars on Positive Phase 1 Results for TTI-109, Quiver Quant: Why Tvardi Therapeutics (TVRD) Stock Is Up Today, MarketChameleon: TVRD Press Releases.

Akari Therapeutics (AKTX) — +42.02% on 0.84x volume

Akari Therapeutics gained +42.02% on 0.84x volume on Tuesday after announcing the appointment of Patricia LoRusso, D.O., the former President of the American Association for Cancer Research (AACR), to its Scientific Advisory Board. LoRusso brings more than 25 years of oncology drug-development experience, including early-stage cancer studies and newly developed treatments, and her addition is a credibility signal as Akari prepares to move its lead cancer program toward human trials. Signal class: Single-stock catalyst (leadership credibility). The 0.84x volume is sub-average, suggesting the move is a thin-trade squeeze on relatively modest institutional flow rather than broad accumulation. Akari’s lead program, AKTX-101, recently showed synergistic activity with KRAS inhibition in KRAS-mutated pancreatic cancer models; the SAB addition is positioning for a credible IND-track narrative. The 5d momentum of +59.8% indicates the move is part of a multi-day run-up, not a one-day event. The 75.67% 12-month decline and 5d +59.8% put AKTX in volatile-momentum territory, and TipRanks notes the stock has been paused several times over the past month due to volatility. Watch: a confirmed IND filing or KRAS-pancreatic preclinical update would be the next value-creating event. The LoRusso hire is a credibility hire — it doesn’t change the underlying science, but it changes the credibility of the IND-track narrative. Sources: TipRanks: Akari Therapeutics (AKTX) Stock Rallies on a Scientific Advisory Board Addition, MarketChameleon: AKTX Press Release — Akari Therapeutics Appoints Former AACR President Patricia LoRusso to Scientific Advisory Board (July 7, 2026).

Top 3 Losers — What Drove Them

CollPlant Biotechnologies (CLGN) — -15.85% on 1.08x volume

CollPlant Biotechnologies fell -15.85% on 1.08x volume on Tuesday after filing a 6-K (foreign issuer report) and calling an extraordinary general meeting of shareholders for July 29, 2026 in Tel Aviv to vote on a massive share-capital increase — from 30 million to 500 million authorized ordinary shares — and to amend its corporate charter. The 16.7x expansion in authorized shares is designed to give the company flexibility for future equity financings and strategic deals, but the filing immediately raised dilution concerns among current holders. Signal class: Financing-driven / dilution overhang. CollPlant’s market cap is ~$5M and average daily volume is ~99K, so any material corporate action produces outsized tape moves. The 5d momentum of -1.8% suggests the move is not momentum-driven — it’s the dilution news. Watch: the July 29 EGM vote is the binary event. If approved, the company can issue new shares at the next financing window; if rejected, the existing 30M-share ceiling constrains any new raise and the stock faces hard choices (going-concern or strategic alternatives). The 6-K filing is the formal start of the dilution process; the next 22 days will see the company publish proxy materials and engage with shareholders ahead of the vote. Sources: TipRanks: CollPlant Biotechnologies Calls July 29 Extraordinary Meeting to Approve Major Share Capital Increase, SEC: CollPlant 6-K Foreign Issuer Report — July 7, 2026.

Elicio Therapeutics (ELTX) — -15.02% on 0.42x volume

Elicio Therapeutics fell -15.02% on 0.42x volume on Tuesday after Pomerantz LLP announced a securities-fraud class-action investigation on July 7, 2026 (Globe Newswire 5:28 PM), focused on Elicio’s June 15, 2026 press release reporting Phase 2 AMPLIFY-7P results that missed the pre-specified disease-free survival primary endpoint in the intent-to-treat population. The investigation concerns whether Elicio and certain of its officers and/or directors engaged in securities fraud or other unlawful business practices tied to the AMPLIFY-7P disclosure. Signal class: Litigation overhang on prior-cycle catalyst. This is the third event in the ELTX cascade: June 15 AMPLIFY-7P miss (-70.96%), July 2 offering pricing (-37.35%), and now the July 7 securities-fraud investigation. The 5d momentum of -30.0% reflects the multi-day continuation of the original June 15 -70.96% single-day move. The 0.42x volume is sub-average — this is a thin, persistent overhang, not a panic flush. Watch: the class-action filing window typically opens 30-60 days after the announcement. If a lead plaintiff is appointed and the case survives motion-to-dismiss, ELTX will face a multi-year overhang and continued D&O insurance pressure. The AMPLIFY-7P subgroup signal (HR 0.65 in R0) and the refined Phase 3 plan remain the operational thesis; the legal thesis is the overhang. The EGM outcome on July 29 will set the dilution path; the class-action will set the litigation path. ELTX is now a name with two independent overhangs to clear before the operational thesis can re-rate. Sources: MarketChameleon: ELTX Press Release — Pomerantz Law Firm Investigates Claims on Behalf of Investors of Elicio Therapeutics (July 7, 2026), Globe Newswire: Pomerantz LLP Investigates Elicio Therapeutics, Inc. — ELTX (July 7, 2026, 5:28 PM).

CapsoVision (CV) — -14.22% on 1.78x volume

CapsoVision fell -14.22% on 1.78x volume on Tuesday with no fresh public catalyst identified. The 5d momentum of -24.8% confirms the move is the continuation of a multi-day slide off the early-summer highs, and the 1.78x volume is moderate — institutional-grade but not capitulation-grade. CapsoVision is a commercial-stage medical-technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, with a March 26, 2026 Q4 2025 / full-year 2025 earnings release as the most recent operational disclosure. The 12-month price chart shows the stock was up 57.76% over the prior 12 months and is now down 5.84% over the past 30 days, suggesting profit-taking on a longer-term gain. Signal class: Sell-the-news / profit-taking on a multi-week slide. No fresh July 7 catalyst; the move is technical continuation, not news-driven. Watch: the next material event is the Q2 2026 earnings release, expected in early August. A clean print on capsule-endoscopy system placements and AtHome Capsule revenue would be the next value-creating event. If the slide continues into the Q2 print without a catalyst, the technical move extends. Prior-cycle catalyst — flagged. Sources: CapsoVision News, FinanceCharts: CV Stock Price History Charts.

The Cross-Cutting Pattern

Today’s session is a clean catalyst-driven tape — the first in over a week. The top six movers are anchored by one Class-3 (Buyout / strategic capital), one Class-2 (Single-stock clinical event), one Class-2 (Single-stock catalyst, leadership credibility), one Class-5 (Financing-driven dilution), one Class-5 (Litigation overhang on prior-cycle), and one Class-5 (Profit-taking on multi-week slide). Compare to 2026-07-06 (zero clean catalysts in the top six — all Class-1 or Class-5 mechanical / continuation) and 2026-07-02 (one Class-2 Phase-2 miss, one Class-1 buyback, one Class-3 strategic-capital). The shift from Class-1-and-5 to Class-2-and-3 is the macro story.

The Vertex–Crinetics $10B deal is the day’s macro tailwind. The deal is one of the largest biotech acquisitions of 2026, and it set the tone for the rest of the tape: the XBI +1.90% outperformed the IBB +1.50% and the XLV +1.53%, indicating that small-cap biotech (the buyout target’s market segment) was the prime beneficiary. The Antibodies and RNA, Peptide & Gene Therapy sector averages (the two categories with the highest M&A and strategic-partnership potential) led the day, while AI/ML and Devices — Imaging lagged. The pattern is consistent with the late-June / early-July M&A window: AbbVie–Apogee (June 22, $10.9B), Definium–AbbVie (June 25, $10.9B), and now Vertex–Crinetics (July 7, $10B) — three >$10B biotech deals in three weeks.

Volume confirms direction, not magnitude. The biggest winners (CRNX +98.74%, TVRD +54.23%, AKTX +42.02%) had volume ratios of 18.41x, 24.17x, and 0.84x respectively. CRNX and TVRD are the two clean institutional-grade flows of the day; AKTX is a thin-trade squeeze. The biggest losers (CLGN -15.85%, ELTX -15.02%, CV -14.22%) had volume ratios of 1.08x, 0.42x, and 1.78x — none of the three is capitulation-grade. The next session’s follow-through will be a function of which names have real institutional positioning (CRNX, TVRD, CLGN’s dilution vote) and which are mechanical (CV’s profit-taking, ELTX’s litigation overhang).

A note on the clean-catalyst day. When the top six movers are anchored by Class-2 and Class-3 catalysts, the daily synthesis has higher information value than on a zero-clean-catalyst day. The Vertex–Crinetics deal is the year’s largest strategic-capital print since the AbbVie–Apogee transaction; the TVRD Phase 1 readout is a multi-signal credibility catalyst on a previously thinly-traded microcap; the AKTX SAB addition is a credibility hire on a 5d +59.8% run-up; the CLGN dilution vote is a binary event 22 days out; the ELTX litigation probe is the third leg of a three-week cascade; the CV slide is a profit-taking continuation with no fresh catalyst. Each of these tells a different story, and the next session will resolve which stories have follow-through.

The 5 Data Points That Matter

When you read a daily biotech mover report, these five columns tell you 90% of the story. Use them in this order.

1. % change — direction and magnitude. CRNX at +98.74% on 18.41x volume is institutional-grade buyout flow. TVRD at +54.23% on 24.17x volume is institutional-grade clinical-event flow. CLGN at -15.85% on 1.08x volume is dilution-overhang flow. CV at -14.22% on 1.78x volume is moderate profit-taking. The volume ratio is what distinguishes the four.

2. Volume ratio — confirms or denies the price action. CRNX at 18.41x and TVRD at 24.17x are the two clean institutional-grade flows of the day. CLGN at 1.08x is dilution-overhang flow (the company’s market cap is ~$5M with ~99K average daily volume, so 1.08x is enough to move the stock 15%). ELTX at 0.42x is litigation-overhang continuation (sub-average, thin-trade). The CRNX and TVRD numbers are the institutional-grade tells.

3. 5d momentum — tells you whether today is the start of a move or the end. CRNX at 5d +126.1% indicates the market was positioning into the announcement over the past week. TVRD at 5d +62.3% indicates the prodrug design has been building credibility since the company’s earlier disclosures. AKTX at 5d +59.8% indicates the move is part of a multi-day run-up. CLGN at 5d -1.8% indicates the move is fresh news, not continuation. ELTX at 5d -30.0% indicates the litigation probe is the third leg of a multi-week cascade. CV at 5d -24.8% indicates the slide is multi-week profit-taking.

4. Sector context — Antibodies at +2.69% (n=42) and RNA, Peptide & Gene Therapy at +2.33% (n=27) are the day’s broad-based sector leaders. Small Molecule Pharma at +2.15% (n=154) is the largest category. AI/ML at -5.67% (n=6), Devices — Imaging at -4.01% (n=8), and Cannabis-related at -4.04% (n=4) are the small-sample laggards. The CRNX deal flows into the small-cap biotech and Antibodies buckets; the TVRD readout is a single-name flow in the small-molecule-pharma bucket.

5. Catalyst calendar — the Vertex–Crinetics deal close in Q3 2026, the TVRD Phase 2 initiation in hepatocellular carcinoma and other STAT3-driven indications, the CLGN July 29 EGM vote on the 16.7x share-capital increase, the ELTX class-action filing window 30-60 days out, the CV Q2 2026 earnings release in early August, the AKTX IND filing or KRAS-pancreatic preclinical update. For mid-cap and large-cap biotech, the catalyst calendar drives the technical tape; for microcaps, the dilution / compliance / EGM calendar drives the tape.

What This Synthesis Will and Won’t Tell You

It will tell you what moved on 2026-07-07, the 6-class taxonomy of those moves (clean Class-2 and Class-3 anchored, with Class-5 dilution / litigation / profit-taking on the downside), the top winners and losers with their most-likely catalyst categories (CRNX — Vertex buyout; TVRD — Phase 1 readout; AKTX — SAB hire; CLGN — dilution EGM; ELTX — securities-fraud probe; CV — profit-taking), and the cross-cutting pattern (clean catalyst tape, M&A tailwind, XBI leading XLV, Antibodies / RNA leading AI/ML / Imaging).

It will not tell you the forward direction (one day is one day), whether the Vertex–Crinetics deal will close on schedule (regulatory risk is real), whether the TVRD Phase 2 will read out successfully in HCC (the prodrug design is validated, but Phase 2 is a different hurdle), whether the CLGN EGM will approve the 16.7x share-capital expansion (binary event 22 days out), whether the ELTX class-action will be filed and survive motion-to-dismiss (litigation outcome is 12-24 months out), or whether the CV Q2 2026 print will restore the uptrend (operational, not technical, question). All of these are 30-day-to-12-month decisions, not single-day decisions.

One day is one day. A 142-anomaly catalyst-driven day could be the start of a 2-3 week M&A-and-data-driven window (the late-June / early-July M&A streak continues), or it could be a one-off catalyst day that resolves quickly. The Q2 earnings season starts in mid-July for the early reporters, and the data-readout calendar thickens between now and the August medical meetings. The next 10 sessions will be dominated by M&A continuation, clinical readouts, and Q2 earnings — not mechanical flows.

---

This is editorial analysis, not investment advice. YTD returns reflect single-day pricing on 2026-07-07 and will move with market conditions and clinical readouts. Several top performers carry volatility flags — review the watch-flag notes for TVRD (24x volume on a microcap), AKTX (75.67% 12-month decline, multiple volatility pauses), and CLGN (microcap dilution vote pending) before drawing conclusions about momentum durability.

The full report (587 companies, all sector tables, full methodology, the “Why the top movers moved” investigation with citations) is in the published analysis archive at openbionews.com. The “why” investigation was run via web search of public company press releases, SEC filings, and financial-news services (Stock Titan, TipRanks, MarketChameleon, InvestorIdeas, Intellectia, Quiver Quant, Globe Newswire) on Tuesday, July 7, 2026 PT.

Generated 2026-07-07 PT (post-market, after 4 PM ET close). Source: Nasdaq public quote API for prices and volumes; public company press releases, SEC filings, and financial-news services (Stock Titan, TipRanks, MarketChameleon, InvestorIdeas, Intellectia, Quiver Quant, Globe Newswire) for the catalyst investigation. Sector categorization is indexed from public company self-descriptions. Bulk fetch elapsed: 330.1s; 587 saved, 2 skipped, 11 errors.

OpenBio News is a daily summary of the life-sciences news cycle, generated from primary public sources (Fierce Pharma, STAT News, Endpoints News, Nasdaq public quote API, public company press releases and SEC filings). The full analysis archive is at openbionews.com/analysis. For the daily biotech movers series, see the prior syntheses at Daily Biotech Movers — 2026-07-06 (zero-clean-catalyst day), Daily Biotech Movers — 2026-07-03 (pre-holiday retread), and Daily Biotech Movers — 2026-07-02 (buybacks and Phase 2 fails).